Earnings Releases·Nov 5, 2026, 4:20 PM ET

vTv Therapeutics — Third Quarter 2026 Earnings Summary

Reported a net loss of $11.6 million ($0.94 per share) for Q3 2026, an improvement from $8.7 million ($1.08 per share) in the prior year period, while nine-month net loss narrowed to $0.5 million ($0.04 per share) from $19.8 million ($2.80 per share) in 2025.
Completed enrollment in the Phase 3 CATT1 trial for cadisegliatin in type 1 diabetes and randomized the first participant in the Phase 2a Hybrid CATT1 pilot study; topline data for CATT1 is expected in mid-2027.
Secured FDA Orphan Drug Designation for HPPD, a potential treatment for sickle cell disease, and reported total stockholders' equity increased to $69.7 million as of September 30, 2026.
Cash and cash equivalents decreased to $77.2 million as of September 30, 2026, from $88.9 million at year-end 2025, with management confirming sufficient funds to support operations through the anticipated mid-2027 trial readout.
Revenue remained $0 for the three-month period but reached $36.8 million for the nine months ended September 30, 2026, compared to $0 in the prior year period.